Guo Jing-Feng, Zhang Bo, Wu Feng, Wang Bing, Xing Hui, Zhu Guan-Yu, Nie Xiang-Yang, Peng Jing
Hexian Memorial Hospital, Guangzhou, Guangdong 511400, P.R. China.
Chin J Cancer. 2010 Mar;29(3):321-4. doi: 10.5732/cjc.009.10432.
Accumulating data indicate that docetaxel plus cisplatin and 5-fluorouracil has certain effect on advanced gastric or gastro-oesophageal junction adenocarcinoma. This study was to evaluate the efficacy and toxicity of docetaxel plus nedaplatin and 5-fluorouracil (DNF regimen) in treating advanced esophageal carcinoma.
Forty-three patients with pathologically confirmed advanced esophageal carcinoma treated by DNF regimen: intravenous infusion of docetaxel (75 mg/m(2)) over 1 h, intravenous infusion of nedaplatin (100 mg/m(2)) over 3 h, intravenous infusion of leucovorin (CF, 200 mg/m(2)) over 2 h, intravenous injection of 5-fluorouracil (375 mg/m(2)) over 10 min, followed by a 46-hour infusion of 5-fluorouracil (2.6 g/m(2)). The cycle was repeated every three weeks. Treatment efficacy was evaluated every two weeks according to the WHO standards. All patients received at least two cycles of chemotherapy.
Patients received a total of 144 cycles of treatment, and all were evaluable for efficacy and toxicity. Of the 43 patients, 2 (4.65%) achieved complete response (CR), 25 (58.14%) achieved partial response (PR), 9 (20.93%) had stable disease (SD), and 7 (16.28%) had progressive disease (PD). The overall response rate was 62.8%. The median time-to-progression (TTP) was 201 days and the median survival time (MST) was 310 days. Grade III/IV adverse events mainly included neutropenia (20.93%), febrile neutropenia (4.65%), thrombocytopenia (6.98%) and vomiting (9.30%). One patient died of grade IV thrombocytopenia.
DNF regimen is effective for and well tolerated by patients with advanced esophageal carcinoma.
越来越多的数据表明，多西他赛联合顺铂和5-氟尿嘧啶对晚期胃癌或胃食管交界腺癌有一定疗效。本研究旨在评估多西他赛联合奈达铂和5-氟尿嘧啶（DNF方案）治疗晚期食管癌的疗效和毒性。
43例经病理确诊的晚期食管癌患者接受DNF方案治疗：多西他赛（75mg/m²）静脉滴注1小时，奈达铂（100mg/m²）静脉滴注3小时，亚叶酸钙（CF，200mg/m²）静脉滴注2小时，5-氟尿嘧啶（375mg/m²）静脉推注10分钟，随后46小时持续静脉滴注5-氟尿嘧啶（2.6g/m²）。每三周重复一个周期。每两周根据世界卫生组织标准评估治疗疗效。所有患者至少接受两个周期的化疗。
患者共接受144个周期的治疗，所有患者均可评估疗效和毒性。43例患者中，2例（4.65%）达到完全缓解（CR），25例（58.14%）达到部分缓解（PR），9例（20.93%）病情稳定（SD），7例（16.28%）病情进展（PD）。总缓解率为62.8%。中位疾病进展时间（TTP）为201天，中位生存时间（MST）为310天。Ⅲ/Ⅳ级不良事件主要包括中性粒细胞减少（20.93%）、发热性中性粒细胞减少（4.65%）、血小板减少（6.98%）和呕吐（9.30%）。1例患者死于Ⅳ级血小板减少。
DNF方案对晚期食管癌患者有效且耐受性良好。
